Source-grounded facts extracted from ASSEMBLY BIOSCIENCES, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
ASSEMBLY BIOSCIENCES, INC. shareholders approved Approval of ESPP Amendment No. 2 to increase shares reserved to 515,000 at the 2026-06-04 meeting.
“The stockholders approved the ESPP Amendment No. 2 to increase the number of shares reserved under the ESPP to 515,000 shares.”
ASSEMBLY BIOSCIENCES, INC. shareholders approved Approval of Amendment No. 3 to 2018 Plan to increase shares reserved by 1,200,000 at the 2026-06-04 meeting.
“The stockholders approved Amendment No. 3 to the 2018 Plan to increase the number of shares reserved for issuance under the 2018 Plan by 1,200,000 shares.”
ASSEMBLY BIOSCIENCES, INC. shareholders approved Ratification of Ernst & Young LLP as independent auditor for fiscal year 2026 at the 2026-06-04 meeting.
“The stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
ASSEMBLY BIOSCIENCES, INC. shareholders approved Advisory vote on named executive officers' compensation at the 2026-06-04 meeting.
“The stockholders approved, on a non-binding advisory basis, the Company's named executive officers' compensation disclosed in the Proxy Statement.”
ASSEMBLY BIOSCIENCES, INC. shareholders approved Election of nine directors to serve until the 2027 annual meeting at the 2026-06-04 meeting.
“The stockholders elected of the following to serve on the Company's Board of Directors until the Company's 2027 annual meeting of stockholders and until their successors are duly elected and qualified: Anthony E. Altig; Tomas Cihlar, Ph.D.; Gina Consylman; Robert D. Cook II; Sir Michael Houghton, Ph.D.; Lisa R. Johnson-Pratt, M.D.; Susan Mahony, Ph.D.; John G. McHutchison, A.O., M.D.; and Jason A. Okazaki.”
ASSEMBLY BIOSCIENCES, INC. entered into Underwriting Agreement with Guggenheim Securities, LLC and UBS Securities LLC, as representatives of the several underwriters valued at approximately $107.4 million (effective 2026-05-21).
“On May 21, 2026, Assembly Biosciences, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Guggenheim Securities, LLC ("Guggenheim Securities") and UBS Securities LLC, as representatives of the several underwriters listed in Schedule A thereto (the "Underwriters"), in connection with the issuance and sale, in an underwritten, registered offering (the "Offering"), of: (1) 3,358,602 shares (the "Offering Shares") of the Company's common stock, par value $0.001 per share (the " Common Stock "), at an offering price of $26.50 per share; and (2) pre-funded warrants (the "Pre-Funded Warrants") to purchase up to an aggregate of 415,000 shares of Common Stock (the "Pre-Funded Warrant Shares"), at an offering price of $26.499 per Pre-Funded Warrant.”
ASSEMBLY BIOSCIENCES, INC. reported the quarter ended March 31, 2026 results: revenue $8.2 million, net income Net loss attributable to common stockholders was $9.1 million, or $0.54 per basic and diluted share, EPS $0.54 per basic and diluted share.
“compared to $248.1 million as of December 31, 2025. The company’s cash position is projected to fund operations into 2028. • Revenue from collaborative research with Gilead was $8.2 million for the three months ended March 31, 2026, compared to $9.4 million for the same period in 2025. The decrease reflects the timing of activities performed and progress toward”
ASSEMBLY BIOSCIENCES, INC. reported the year ended December 31, 2025 results: revenue $72.3 million, net income Net loss attributable to common stockholders was $6.1 million, EPS $0.55 per basic and diluted share.
“Year-End 2025 Financial Results • Cash, cash equivalents and marketable securities were $248.1 million as of December 31, 2025, compared to $232.6 million as of September 30, 2025, and $112.1 million as of the year ended December 31, 2024. The company’s cash position is projected to fund operations into 2028. • Revenue from collaborative research with Gilead was $72.3 million for the year ended December 31, 2025, compared to $28.5 million in 2024. The increase reflects the increase in collaboration funding. • Research and development expenses were $64.8 million for the year ended December 31, 2025, compared to $55.9 million in 2024. The increase is largely driven by an increase in spending on the HPI program, as both ABI-1179 and ABI-5366 saw significant enrollment in their respective Phase 1b clinical studies during the current year. • General and administrative expenses were $19.6 million for the year ended December 31, 2025, compared to $18.0 million in 2024. The increase was primar”
Jason A. Okazaki changed role as principal executive officer at ASSEMBLY BIOSCIENCES, INC..
“Ms. Bjorkquist succeeds Jason A. Okazaki, who previously served as both the Company’s principal executive officer and principal financial officer.”
Jeanette M. Bjorkquist was appointed as principal financial officer at ASSEMBLY BIOSCIENCES, INC..
“On June 5, 2025, the Board of Directors appointed Jeanette M. Bjorkquist to serve as the Company’s principal financial officer in addition to her role as principal accounting officer.”
ASSEMBLY BIOSCIENCES, INC.: Amended and restated bylaws to update advance notice provisions, deadlines, proxy card color, director nominee requirements, and stockholder notice updates (effective 2024-12-12).
“On December 12, 2024, the Board of Directors (the “Board”) of Assembly Biosciences, Inc. (the “Company”) approved an amendment and restatement of the Company’s Amended and Restated Bylaws (the “Amended Bylaws”), effective as of such date.”
ASSEMBLY BIOSCIENCES, INC. reported first quarter ended March 31, 2024 results: revenue $5.8 million, net income $9.1 million, EPS $1.66 per basic and diluted share.
“to $130.2 million as of December 31, 2023. Assembly Bio’s cash position is projected to fund operations into the second half of 2025. • Revenues from collaborative research were $5.8 million for the three months ended March 31, 2024. There was no revenue recognized for the same period in 2023. Revenue for the three months ended March 31, 2024 consists of amounts”
ASSEMBLY BIOSCIENCES, INC. reported the quarter and year ended December 31, 2023 results: revenue $7.2 million, net income $61.2 million, EPS $13.38 per basic and diluted share.
“as of the year ended December 31, 2022. The company’s cash position is projected to fund operations into the second half of 2025. • Revenues from collaborative research were $7.2 million for the year ended December 31, 2023. There was no revenue recognized for the same period in 2022. Revenue for the year ended December 31, 2023, consists of $4.4 million”
Robert D. Cook II was appointed as Director at ASSEMBLY BIOSCIENCES, INC..
“On March 13, 2024, the Board appointed Robert D. Cook II, a designee of Gilead Sciences, Inc. ("Gilead"), to serve on the Board.”
ASSEMBLY BIOSCIENCES, INC.: Filed an amendment to the Sixth Amended and Restated Certificate of Incorporation to effect a 1-for-12 reverse stock split (effective 2024-02-09).
“On February 9, 2024, Assembly Biosciences, Inc. (the "Company"), filed an amendment (the "Amendment") to its Sixth Amended and Restated Certificate of Incorporation (the "Charter") with the Secretary of State of the State of Delaware to effect a 1-for-12 reverse stock split (the "Reverse Stock Split") of the Company's common stock, par value $0.001 (the "Common Stock"). The Amendment became effective on February 9, 2024.”
ASSEMBLY BIOSCIENCES, INC. shareholders approved Adjournment of the Special Meeting to solicit additional proxies if necessary at the 2024-01-31 meeting.
“The stockholders approved an adjournment of the Special Meeting to a later date or dates, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the foregoing proposals.”
ASSEMBLY BIOSCIENCES, INC. shareholders approved Issuance of shares of common stock to Gilead Sciences, Inc. pursuant to Nasdaq Listing Rules 5635(a) and 5635(b) at the 2024-01-31 meeting.
“The stockholders approved, subject to certain conditions, the issuance of shares of common stock to Gilead Sciences, Inc. ("Gilead") pursuant to Nasdaq Listing Rules 5635(a) and 5635(b).”
ASSEMBLY BIOSCIENCES, INC. shareholders approved Reverse stock split at ratio from 1-for-7 to 1-for-17 at the 2024-01-31 meeting.
“The stockholders approved a series of alternate amendments to the Company's Sixth Amended and Restated Certificate of Incorporation to effect, at the discretion of the Company's Board of Directors (the "Board"), a reverse stock split of the Company's common stock at a ratio to be determined by the Board within a range of 1-for-7 to 1-for-17 (or any number in between) without reducing the authorized number of shares of the common stock.”
ASSEMBLY BIOSCIENCES, INC. terminated Exclusive License Agreement with Indiana University Research and Technology Corporation (effective 2024-01-11).
“On January 11, 2024, Assembly Biosciences, Inc. (the "Company") notified the Indiana University Innovation and Commercialization Office that the Company has decided to terminate the Exclusive License Agreement dated September 3, 2023 by and between Indiana University Research and Technology Corporation ("IURTC") and Assembly Pharmaceuticals, Inc., the Company's predecessor (the "License Agreement"), as amended by Amendment No. 1 to the License Agreement dated February 28, 2017 and Amendment No. 2 to the License Agreement dated July 10, 2020.”
Tomas Cihlar was appointed as Board Member at ASSEMBLY BIOSCIENCES, INC..
“On December 7, 2023, the Board of Directors (the "Board") of Assembly Biosciences, Inc. (the "Company") appointed Tomas Cihlar, Ph.D., a designee of Gilead Sciences, Inc. ("Gilead"), to serve on the Board.”
ASSEMBLY BIOSCIENCES, INC. reported the third quarter ended September 30, 2023 results: net income Net loss attributable to common stockholders was $14.4 million, or $0.27 per basic and diluted share.
“Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today reported financial results for the third quarter ended September 30, 2023, and recent corporate updates.”
ASSEMBLY BIOSCIENCES, INC. entered into Common Stock Purchase Agreement and Investor Rights Agreement with Gilead Sciences, Inc. valued at $15 million equity investment; 13,073,668 shares of common stock at $1.16 per share; potential addit (effective 2023-10-15).
“In addition to the Collaboration Agreement, the Company and Gilead entered into a Common Stock Purchase Agreement and an Investor Rights Agreement (collectively, the “Equity Agreements”), pursuant to which Gilead made an upfront equity investment of $15 million by purchasing from the Company 13,073,668 shares of the Company’s common stock (“Common Stock”) at a purchase price of $1.16 per share.”
ASSEMBLY BIOSCIENCES, INC. entered into Option, License and Collaboration Agreement with Gilead Sciences, Inc. valued at $85 million upfront cash payment, $15 million equity investment, extension fees of $75 million per p (effective 2023-10-15).
“On October 15, 2023, Assembly Biosciences, Inc. (the “Company”) entered into an Option, License and Collaboration Agreement (“Collaboration Agreement”) with Gilead Sciences, Inc. (“Gilead”) pursuant to which Gilead will (1) exclusively license to the Company its helicase primase inhibitor program and non-nucleoside polymerase inhibitor (NNPI) program, while retaining opt-in rights to these programs and (2) have an option to take an exclusive license, on a program-by-program basis, to all of the Company’s other current and future pipeline programs.”
ASSEMBLY BIOSCIENCES, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“September 27, 2023, Assembly Biosciences, Inc. (the "Company") received a letter from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") notifying the Company that, as the bid price for the Company's common stock, par value $0.001 per share (the "Common Stock"), had closed below $1.00 per share for the last 30 consecutive business days, the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1), which is the minimum bid price requirement for continued listing on the Nasdaq Global Select Market. Nasdaq's notice has no immediate effect on the listing of the Co”
ASSEMBLY BIOSCIENCES, INC. reported the quarter ended June 30, 2023 results: net income $16.9 million, or $0.32 per basic and diluted share, EPS $0.32 per basic and diluted share.
“Net loss attributable to common stockholders was $16.9 million, or $0.32 per basic and diluted share, for the three months ended June 30, 2023, compared to $24.5 million, or $0.51 per basic and diluted share, for the same period in 2022.”
ASSEMBLY BIOSCIENCES, INC. entered into Sublease with Arsenal Biosciences, Inc. valued at Monthly base rent of $109,906.50 for months 1-12 and $113,753.23 for months 13-24; security deposit (effective 2023-08-04).
“On August 4, 2023, Assembly Biosciences, Inc. (the “Company”) and Arsenal Biosciences, Inc. (the "Sublessor") entered into a Sublease for the Company’s lease of approximately 20,000 square feet of office and laboratory space (the "Sublease"), which will serve as the Company's corporate headquarters, located at 2 Tower Place, 7th Floor, South San Francisco, California (the "Premises").”
ASSEMBLY BIOSCIENCES, INC. reported first quarter ended March 31, 2023 results: net income $19.0 million, EPS $0.37 per basic and diluted share.
“Net loss attributable to common stockholders was $19.0 million, or $0.37 per basic and diluted share, for the three months ended March 31, 2023”
ASSEMBLY BIOSCIENCES, INC. reported financial results for the fourth quarter and year ended December 31, 2022.
“On March 22, 2023, Assembly Biosciences, Inc. (the "Company") issued a press release (the "Press Release") announcing its financial results for the quarter and year ended December 31, 2022 and recent corporate highlights.”
ASSEMBLY BIOSCIENCES, INC.: Amended and restated Bylaws reducing stockholder meeting quorum from majority to one-third, deleting list of stockholders requirement, and updating advance notice provisions for universal proxy rules (effective 2022-12-07).
“On December 7, 2022, the Board approved an amendment and restatement of the Company's Amended and Restated Bylaws (the "Amended and Restated Bylaws").”
Jason A. Okazaki was appointed as Chief Executive Officer at ASSEMBLY BIOSCIENCES, INC..
“Jason A. Okazaki, the Company's President and Chief Operating Officer, would succeed Dr. McHutchison as Chief Executive Officer, effective January 1, 2023”
John G. McHutchison departed as Chief Executive Officer at ASSEMBLY BIOSCIENCES, INC..
“John G. McHutchison, A.O., M.D. would retire from his role as Chief Executive Officer effective December 31, 2022”
ASSEMBLY BIOSCIENCES, INC. reported the third quarter ended September 30, 2022 results: net income Net loss attributable to common stockholders was $23.1 million, or $0.48 per basic and diluted share, EPS $0.48 per basic and diluted share.
“Assembly Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights and Announces Upcoming Conference Participation”
John G. McHutchison changed role as Chief Executive Officer at ASSEMBLY BIOSCIENCES, INC..
“John G. McHutchison, A.O., M.D. will retire from his role as Chief Executive Officer of the Company, effective December 31, 2022.”
Jason A. Okazaki changed role as President and Chief Operating Officer at ASSEMBLY BIOSCIENCES, INC..
“on July 19, 2022, the Board promoted Mr. Okazaki to President and Chief Operating Officer.”
Michael P. Samar departed as Chief Financial Officer at ASSEMBLY BIOSCIENCES, INC..
“Michael P. Samar will depart his roles as the Company's Chief Financial Officer, principal financial officer and principal accounting officer effective August 12, 2022.”
Michael P. Samar changed role as Chief Financial Officer at ASSEMBLY BIOSCIENCES, INC..
“Michael P. Samar, 49, has been promoted to the position of Chief Financial Officer.”
Jason A. Okazaki changed role as Chief Operating Officer at ASSEMBLY BIOSCIENCES, INC..
“Jason A. Okazaki, 45, has been promoted to the position of Chief Operating Officer”
Michael Houghton was appointed as Director at ASSEMBLY BIOSCIENCES, INC..
“On July 19, 2021, the Board of Directors (the “Board”) of Assembly Biosciences, Inc. (the “Company”) appointed Michael Houghton, Ph.D. as an independent, non-employee member of the Board effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.